Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Phase 2/3 × Enrolling by invitation × 90 days × Clear all

Phase

Phase NA 45 Phase 2 16 Phase 3 8 Phase 1 3 Phase EARLY_PHASE1 2 Phase 2/3 2 Phase 1/2 2

Status

Recruiting 71 Active not recruiting 29 Not yet recruiting 26 Completed 11 Suspended 5 Terminated 2 Enrolling by invitation 2

Sponsor Class

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 1 Myasthenia Gravis 1 Cholangiocarcinoma 1

Interventions

futibatinib 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06506955 2026-03-11

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Taiho Oncology, Inc.

Phase 2/3 Enrolling by invitation

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT05374590 2026-02-02

ADAPT Jr +

argenx

Phase 2/3 Enrolling by invitation

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡